Early primary renal tumor response predicts clinical outcome in patients with primary unresectable renal cell carcinoma with synchronous distant metastasis receiving molecularly targeted therapies.

about

Early primary renal tumor response predicts clinical outcome in patients with primary unresectable renal cell carcinoma with synchronous distant metastasis receiving molecularly targeted therapies.

Item

http://www.wikidata.org/entity/Q41162248

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Early primary renal tumor resp ...... olecularly targeted therapies.

@en

type

Item

label

Early primary renal tumor resp ...... olecularly targeted therapies.

@en

prefLabel

Early primary renal tumor resp ...... olecularly targeted therapies.

@en

P1476

Early primary renal tumor resp ...... olecularly targeted therapies.

@en

P2093

Hirofumi Kurose

http://www.w3.org/2001/XMLSchema#string

Hiroki Suekane

http://www.w3.org/2001/XMLSchema#string

Katsuaki Chikui

http://www.w3.org/2001/XMLSchema#string

Kazuhisa Ejima

http://www.w3.org/2001/XMLSchema#string

Kiyoaki Nishihara

http://www.w3.org/2001/XMLSchema#string

Kosuke Ueda

http://www.w3.org/2001/XMLSchema#string

Makoto Nakiri

http://www.w3.org/2001/XMLSchema#string

Mitsunori Matsuo

http://www.w3.org/2001/XMLSchema#string

Naoyuki Ogasawara

http://www.w3.org/2001/XMLSchema#string

Shigetaka Suekane

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.

Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma.

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).

Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis.

Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma.

Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

P304

205-210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2017.1294

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28781786

http://www.w3.org/2001/XMLSchema#string

P932

5532700

http://www.w3.org/2001/XMLSchema#string